Weight loss drugs known as GLP-1 receptor agonists are sometimes referred to as “miracle drugs,” not only because they help people lose weight, but because they’ve also been shown to help with many ...

"Our findings that [GLP-1 receptor agonists] are associated with decreases in RA disease activity, cardiovascular risk factors, and pain in patients with RA and overweight or obesity are promising and ...

GLP-1 RA use was associated with significant weight loss in patients with IBD and obesity and/or T2D, with mean differences of -9.1 kg in semaglutide users, -9 kg in liraglutide users, and -11.6 kg in ...

Bagsværd, Denmark, 15 September 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the ...

The incidence rates of the 14 cancers were 13.6 and 16.4 per 1000 person-years, respectively, with a significantly lower overall cancer risk among GLP-1 RA users vs nonusers. HealthDay News — For ...

Hispanic, Black non-Hispanic, White non-Hispanic adults more likely to use GLP-1 RA injectables than Asian non-Hispanics. (HealthDay News) — In 2024, 26.5 percent of adults with diagnosed diabetes ...

GLP-1RA use improves major cardiovascular and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is ...

BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the ...

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo COYA 303 is an investigational ...

Treatment with glucagon-like peptide-1 receptor agonists was associated with lower probabilities of heart, kidney, and lung complications after partial nephrectomy for RCC.

Odds of vertebral compression fractures or surgical intervention were significantly lower among GLP-1 RA users ...